Allosteric Bioscience

Allosteric Bioscience is an early-stage, private biotech leveraging computational and AI-driven methods to discover allosteric modulators for CNS disorders. The company has licensed a sarcopenia (muscle loss) prevention/treatment technology from Johns Hopkins University, indicating an expansion beyond its core neurological focus. Its positioning at the convergence of quantum computing and biology suggests a highly ambitious, platform-based strategy, though the company appears to be in a pre-clinical or discovery stage with no disclosed pipeline candidates.

AI and machine learning platform, with aspirational quantum computing integration, focused on the discovery of novel allosteric modulators for disease targets.

Competes in the crowded AI-driven drug discovery sector against companies like Recursion, Exscientia, and Relay Therapeutics, as well as large pharma internal efforts. Specifically in allosteric modulation, it faces competition from biotechs like Sosei Heptares and Confo Therapeutics.